Emergent Management of Acute Infarct with Severe Eye Pain and Headache
Immediately initiate high-dose intravenous methylprednisolone empirically while simultaneously triaging for STAT ophthalmological examination and pursuing parallel workup for both giant cell arteritis (GCA) and central retinal artery occlusion (CRAO), with consideration of IV thrombolysis if CRAO is confirmed within 4.5 hours of symptom onset.
Initial Triage and Parallel Workflow
The combination of acute infarct with severe eye pain and headache demands immediate action on two fronts: ruling out GCA (which requires immediate steroids) and determining candidacy for thrombolysis if CRAO is confirmed 1.
Immediate GCA Assessment
- Palpate temporal arteries for tenderness, nodularity, or absent pulse
- Draw ESR and CRP immediately if any clinical suspicion exists
- Do not delay steroid treatment while awaiting temporal artery biopsy or imaging confirmation 2
- In patients over 50 years with acute retinal or optic nerve ischemia, GCA must be actively excluded 3, 4
Simultaneous CRAO Evaluation Protocol 1
Step 1: Establish time last known well
- This is critical as thrombolysis efficacy depends on the 4.5-hour window
- Every minute counts for retinal salvage 5, 6
Step 2: Obtain CT brain
- Exclude hemorrhage and other contraindications to thrombolysis
- Follow institutional stroke protocol screening
Step 3: Ophthalmological examination
- STAT fundoscopy or fundus photography via tele-ophthalmology
- Document baseline visual acuity with correction
- Perform confrontation visual fields
- Look for cherry-red spot, retinal whitening, or embolic material 1
Treatment Algorithm
If GCA is Suspected (Any Age ≥50 with Ischemic Symptoms)
Start high-dose IV methylprednisolone immediately - typically 1000 mg daily for 3-5 days, followed by high-dose oral glucocorticoids 2, 3. This is the cornerstone of acute therapy and must not be delayed for diagnostic confirmation.
If Non-Arteritic CRAO is Confirmed
Within 4.5 hours of symptom onset:
- Consider IV thrombolysis with alteplase or tenecteplase after thorough discussion with patient about equipoise in current evidence 1, 5
- The strongest available evidence suggests potential benefit within this narrow window 1, 7
- Risk of symptomatic intracranial hemorrhage appears low when administered within 4.5 hours without concomitant anticoagulation 1
Between 4.5-6 hours at intra-arterial capable center:
- Consider intra-arterial thrombolysis, though evidence is inconsistent and the EAGLE trial showed no benefit (mean treatment time 13 hours) 1
- Risks include arterial dissection, catheter complications, and distal embolization 1
Interventions to AVOID
Do not perform ocular massage, anterior chamber paracentesis, or vasodilator therapy - these have shown no benefit and may be harmful 5.
Critical Pitfalls
- The 4.5-hour window is absolute - delayed presentation is the major challenge limiting effective treatment 5, 6
- GCA can coexist with CRAO - always assess for arteritic causes even when pursuing thrombolysis 1, 3
- Do not wait for temporal artery biopsy before starting steroids if GCA is suspected - biopsy findings remain positive for weeks after steroid initiation 2
- Conservative treatments waste precious time - avoid outdated interventions like ocular massage that have no evidence base 5
Post-Acute Management
After addressing the acute emergency, patients require:
- Complete stroke workup including carotid imaging, cardiac evaluation, and hypercoagulable assessment 7, 4
- Recognition that CRAO carries similar stroke risk as cerebral ischemia 4
- If GCA confirmed, transition to glucocorticoid-sparing agents (tocilizumab or upadacitinib) for long-term disease control 2, 3
The key distinction: CRAO without pain suggests non-arteritic etiology requiring stroke-like management, while severe eye pain and headache significantly raises suspicion for GCA requiring immediate high-dose steroids 3, 4.